Jisung Bae

Jisung Bae

Auto-generated profile, based on publicly available information

Jisung Bae

Department of Anesthesiology and Pain Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2026 in Anesthesia and Pain Medicine
Verified
Journal Article
Open access
PDF file
HKHyosung Kim
Hyosung Kim
BLByung Gun Lim
Byung Gun Lim
YKYoung Sung Kim
Young Sung Kim
SJSeok Woo Jeong
Seok Woo Jeong
JBJisung Bae
Jisung Bae
Background: Sugammadex has recently been approved globally for use in pediatric patients aged ≥ 2 years. This meta-analysis with trial sequential analysis (TSA) evaluated the efficacy and safety of sugammadex for reversal of neuromuscular blockade (NMB) in pediatric patients.Methods: PubMed, EMBASE, the Cochrane Library, Web of Science, Scopus, KoreaMed, and ClinicalTrials.gov were searched from inception to December 31, 2023. Randomized controlled trials (RCTs) evaluating sugammadex in pediatric patients were included. Efficacy outcomes were time to recovery to a train-of-four (TOF) ratio ≥ 0.9 and extubation time. Safety outcomes included overall post-anesthetic adverse events, bradycardia, tachycardia, postoperative nausea and vomiting (PONV), recurarization, and desaturation. Data were analyzed using RevMan, and TSA was performed using Copenhagen Trial Unit software.Results: A total of 21 RCTs (n=1,394 pediatric patients) were included in the study. Time to TOF ratio ≥ 0.9 was significantly shorter with sugammadex than with control (neostigmine or placebo) for both 2 mg/kg (mean difference [95% confidence interval], –6.03 [–7.85 to –4.21] min) and 4 mg/kg (–30.06 [–37.58 to –22.55] min). The extubation time was shorter with sugammadex (–14.26 [–17.22 to –11.30] min). The TSA for both efficacy outcomes indicated that the required information size had been reached, suggesting that additional trials are unlikely to change the efficacy conclusions. PONV, tachycardia, and desaturation occurred less frequently with sugammadex, whereas the overall post-anesthetic adverse events, recurarization, and bradycardia were comparable.Conclusions: Sugammadex was associated with faster and more effective reversal of rocuronium-induced NMB in pediatric patients.

31 October 2026 in Anesthesia and Pain Medicine
Verified
Journal Article
Open access
PDF file
JBJisung Bae
Jisung Bae
BLByung Gun Lim
Byung Gun Lim
ILIl Ok Lee
Il Ok Lee
Benzodiazepines have traditionally been associated with postoperative delirium (POD), but the effect of remimazolam on POD remains uncertain. This systematic review and meta-analysis evaluated the incidence of POD and perioperative safety outcomes associated with remimazolam in adults undergoing general anesthesia. We searched databases from inception through April 27, 2025, and included randomized controlled trials and non-randomized studies comparing remimazolam with conventional anesthetic agents in adults undergoing general anesthesia. The primary outcome was POD incidence, and secondary outcomes comprised perioperative safety measures. We assessed the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Seventeen studies involving 3,180 patients were included. POD incidence did not differ significantly between the remimazolam and control groups (risk ratio [RR], 0.88; 95% confidence interval [CI], 0.71–1.09; I2 = 0%). Similarly, the incidence of intraoperative hypotension did not differ significantly between groups (RR, 0.77; 95% CI, 0.56–1.06). Remimazolam was associated with lower incidences of vasopressor administration (RR, 0.62; 95% CI, 0.41–0.93) and bradycardia (RR, 0.78; 95% CI, 0.62–0.99). Time to eye opening and the incidence of postoperative nausea and vomiting did not differ significantly between groups. The certainty of evidence was very low for POD and low or moderate for secondary outcomes. POD incidence did not differ significantly between remimazolam and conventional anesthetic agents in adults undergoing general anesthesia. Some secondary outcomes suggested a potentially favorable hemodynamic profile; however, the evidence was limited and heterogeneous. Further trials using standardized POD assessment tools and prespecified hemodynamic endpoints are warranted.